Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)

European Journal of Medical Research

Volumn 14, Issue 5, 2009, Pages 195-199

  Arasteh, Keikawus ^a,e   Weitner, L ^b   Fenske, S ^b   Kuhlmann, B ^c   Freiwald, M ^c   Ebrahimi, R ^d   Gallo, L ^d   Ranneberg, B ^d   Mertenskoetter, T ^d  

^a EPIMED   (Germany)

^b IPM Study Center   (Germany)

^c Gilead Sciences ^*

^d Gilead Sciences GmbH   (Germany)

^e Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

Combination therapy; Emtricitabine; HAART; Once daily; Tenofovir DF

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN; CD8 ANTIGEN; CHOLESTEROL; CREATININE; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FECES COLOR; FEMALE; FLATULENCE; FOLLOW UP; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HEMOGLOBIN BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOREGULATION; KIDNEY FUNCTION; KIDNEY PAIN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS TITRATION;

EID: 66549115865     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: 10.1186/2047-783x-14-5-195     Document Type: Article

References (21)

1. Thaker HK, Snow MH: HIV viral suppression in the era of antiretroviral therapy. Postgrad Med J. 2003; 79: 36-42. (Pubitemid 36237877)
2. Panos G, Samonis G, Alexiou VG, Kavarnou GA, Charatsis G, Falagas ME: Mortality and morbidity of HIV infected patients receiving HAART: a cohort study. Curr HIV Res. 2008; 6: 257-260.
3. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, Holmberg SD: Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43: 27-34. (Pubitemid 44306484)
4. Sterne JAC, Herna-n MA, Ledergerber B, Tilling K, Weber R, Sendi P, Rickenbach M, Robins JM, Egger M: Long term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366: 378-384.
5. Kulkosky J, Bray S: HAART-persistent HIV-1 latent reservoirs: their origin, mechanisms of stability and potential strategies for eradication. Curr HIV Res. 2006; 4: 199-208.
6. Delobel P, Sandres-Saune K, Cazabat M, L'Faqihi FE, Aquilina C, Obadia M, Pasquier C, Marchou B, Massip P, Izopet J: Persistence of distinct HIV-1 populations in blood monocytes and naive and memory CD4 T cells during prolonged suppressive HAART. AIDS. 2005; 19: 1739-1750. (Pubitemid 41546592)
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133: 21-30. (Pubitemid 30432540)
8. Stone VE, Hogan JW, Schuman P, Rompalo AM; Howard AA, Korkontzelou C, Smith DK: Antiretroviral Regimen Complexity, Self-Reported Adherence, and HIV Patients' Understanding of Their Regimens: Survey of Women in the HER Study. JAIDS, Vol.28(2), 2001, pp. 124-131.
9. Murri R, Marcotullio S, Lupoli P, von Schloesser F: Is Once-Daily Regimen a Key Strategy for Improving Adherence to Antiretroviral Regimens? JAIDS, Vol.42 (2), 2006, pp. 259-260.
10. Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, Allison J, Chatham A, Raper JL, Kaslow RA, Saag MS, Mugavero MJ: Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008, 22:1951-1960
11. Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better Adherence with Once-Daily Antiretroviral Regimens: A Meta-Analysis. CID 2009, 48: 484-488
12. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD, Brothers CH, Hernandez J, Castillo SA, Bonny T, Lanier ER, Scott TR: Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis. 2004; 39: 1038-1046. (Pubitemid 39313463)
13. Chesney MA: Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000; 30(Suppl 2): S171-S176. (Pubitemid 32268984)
14. Chesney MA, Ickovics J, Hecht FM, Sikipa G, Rabkin J: Adherence: a necessity for successful HIV combination therapy. AIDS. 1999; 13(Suppl A): S271-S278.
15. Conway B: The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007; 45(Suppl 1): S14-S18. (Pubitemid 46828215)
16. Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V: Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial. Antvir Ther. 2005; 10: 825-832. (Pubitemid 41652976)
17. Huffam SE, Srasuebkul P, Zhou J, Calmy A, Saphonn V, Kaldor JM, Ditangko R: Prior antiretroviral therapy experience protects against zidovudine-related anaemia. HIV Med. 2007; 8: 465-471. (Pubitemid 47335269)
18. Semba RD, Martin BK, Kempen JH, Thome JE, Wu AW: The impact of anemia on energy and physical functioning in individuals with AIDS. Arch Intern Med. 2005; 165: 2229-2236. (Pubitemid 41549918)
19. Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A: Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med. 2007; 8: 280-287. (Pubitemid 46901526)
20. DeJesus E, Ruane P, McDonald C, Garcia F, Sharma S for the COMET Team: Impact of Switching Virologically Suppressed, HIV-1-Infected Patients from Twice-Daily Fixed-Dose Zidovudine/Lamivudine to Once-Daily Fixed-Dose Tenofovir Disoproxil Fumarate/Emtricitabine. HIV Clin Trials 2008;9(2):103-114.
21. Moyle G, Fisher M, Reilly G, the SWEET Study Group: A randomized comparison of continued zidovudine plus lamivudine BID (Combivir, CBV) versus switching to tenofovir DF plus emtricitabine (Truvada, TVD) each plus efavirenz (EFV) in stable HIV infected persons: results of a planned 24 week analysis. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention Sydney, Australia, July 2007 [Abstract WEPEB028].